



AMENDMENTS TO THE CLAIMS

1. (Currently amended) The compounds according to the general formula Ia or Ib:




wherein in each

R1 means H, C₁-C₆ alkyl, cycloalkyl, or C₁-C₄ alkylcycloalkyl,

R2 means H, C₁-C₁₄ alkyl, C₂-C₁₄ alkenyl, aryl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ alkylheteroaryl, C₂-C₄ alkenylheteroaryl, cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, C_mH_{2m+o-p}Y_p (with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR₂₁, NH₂, NHR₂₁, NR₂₁R₂₂, and SH, SR₂₁), (CH₂)_rCH₂NHCOR₂₁, (CH₂)_rCH₂OCOR₂₁, (CH₂)_rCH₂NHCSR₂₁, (CH₂)_rCH₂S(O)_nR₂₁, with n

= 0, 1, 2, $(\text{CH}_2)_r\text{CH}_2\text{SCOR}_{21}$, $(\text{CH}_2)_r\text{CH}_2\text{OSO}_2\text{-R}_{21}$, $(\text{CH}_2)_r\text{CHO}$, $(\text{CH}_2)_r\text{CH=NOH}$,
 $(\text{CH}_2)_r\text{CH(OH)R}_{21}$, $-(\text{CH}_2)_r\text{CH=NOR}_{21}$, $(\text{CH}_2)_r\text{CH=NOCOR}_{21}$,
 $(\text{CH}_2)_r\text{CH=NOCH}_2\text{CONR}_{21}\text{R}_{22}$, $(\text{CH}_2)_r\text{CH=NOCH(CH}_3\text{)CONR}_{21}\text{R}_{22}$,
 $(\text{CH}_2)_r\text{CH=NOC(CH}_3\text{)}_2\text{CONR}_{21}\text{R}_{22}$, $(\text{CH}_2)_r\text{CH=N-NHCO-R}_{23}$, $(\text{CH}_2)_r\text{CH=N-NHC(O)NH-R}_{23}$,
 $(\text{CH}_2)_r\text{CH=N-NHC(S)NH-R}_{23}$, $(\text{CH}_2)_r\text{CH=N-NHC(NH)NH-R}_{23}$, $(\text{CH}_2)_r\text{CH=N-NHC(NH)-R}_{23}$,
 $(\text{CH}_2)_r\text{CH=N-NHCO-CH}_2\text{NHCOR}_{21}$, $(\text{CH}_2)_r\text{CH=N-O-CH}_2\text{NHCOR}_{21}$,
 $(\text{CH}_2)_r\text{CH=N-NHCS-R}_{23}$, $(\text{CH}_2)_r\text{CH=CR}_{24}\text{R}_{25}$ (trans or cis), $(\text{CH}_2)_r\text{COOH}$, $(\text{CH}_2)_r\text{COOR}_{21}$,
 $(\text{CH}_2)_r\text{CONR}_{21}\text{R}_{22}$, $-(\text{CH}_2)_r\text{CH=NR}_{21}$, $(\text{CH}_2)_r\text{CH=N-NR}_{21}\text{R}_{22}$,



, and the $(\text{CH}_2)_r$ -chain elongated residue group $(\text{CH}_2)_r\text{CH=N-N-(C}_3\text{NX'R}_{211}\text{R}_{212}\text{R}_{213}\text{R}_{214})$
(with X' = NR₂₁₅, O, S, and R₂₁₁, R₂₁₂, R₂₁₃, R₂₁₄, R₂₁₅ being independently H or C₁-C₆
alkyl), $-(\text{CH}_2)_r\text{CH=N-NHSO}_2$ aryl, or $-(\text{CH}_2)_r\text{CH=N-NHSO}_2$ heteroaryl, with r = 0, 1, 2, 3, 4, 5,

R₂₁, R₂₂ are independently H, C₁-C₁₄ alkyl, C₁-C₁₄ alkanoyl, C₁-C₆ alkylhydroxy, C₁-C₆
alkoxy, C₁-C₆ alkylamino, C₁-C₆ alkylamino-C₁-C₆ alkyl, C₁-C₆ alkylamino-di-C₁-C₆-alkyl,
cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, aryl, aryloyl,
C₁-C₄ alkylaryl, heteroaryl, heteroaryloyl, C₁-C₄ alkylheteroaryl, cycloalkanoyl, C₁-C₄
alkanoylcycloalkyl, heterocycloalkanoyl, C₁-C₄ alkanoylheterocycloalkyl, C₁-C₄ alkanoylaryl,
C₁-C₄ alkanoylheteroaryl, mono- and di-sugar residues groups linked through a C atom which
would carry an OH residue group in the sugar, wherein the sugars are independently selected
from the group consisting of glucuronic acid and its stereoisomers at all optical atoms,
aldopentoses, aldohexoses, including their desoxy compounds (as e.g. glucose, desoxyglucose,
ribose, desoxyribose), or R₂₁ and R₂₂, together with the N, form a ring with 4, 5, 6, 7, or 8

members, which may optionally contain still another heteroatom selected from the group N, O, and S,

R23 independently of R21, has the same meanings as R21, or CH₂-pyridinium salts, CH₂-tri-C₁-C₆ alkylammonium salts, CONH₂, CSNH₂, CN, or CH₂CN,

R24 independently of R21, has the same meanings as R21, or H, CN, COCH₃, COOH, COOR21, CONR21R22, NH₂, or NHCOR21,

R25 independently of R21, has the same meanings as R21, or H, CN, COCH₃, COOH, COOR21, CONR21R22, NH₂, or NHCOR21,

R24, R25 together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, O, and S,

R3 means H, F, Cl, Br, I, OH, OR31, NO₂, NH₂, NHR31, NR31R32, NHCHO, NHCOR31, NHCOCF₃, CH₃-_mhal_m (with hal = Cl, F, and m = 1, 2, 3), or OCOR31,

R31, R32 are independently C₁-C₆ alkyl, or R31 and R32, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, O, and S,

R5 means H, C₁-C₂₀ alkyl, cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, aryl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ alkylheteroaryl, C_mH_{2m+o-p}Y_p (with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR51, NH₂, NHR51, NR51R52, SH, SR21), (CH₂)_sCH₂NHCOR51, (CH₂)_sCH₂NHCSR51, (CH₂)_sCH₂S(O)_nR51, with n = 0, 1, 2, (CH₂)_sCH₂SCOR51, (CH₂)_sCH₂OCOR51, (CH₂)_sCH₂OSO₂-R51, (CH₂)_sCH(OH)R51, (CH₂)_sCOOH, (CH₂)_sCOOR51,

(CH₂)_sCONR51R52, with s = 0, 1, 2, 3, 4, 5, mono- and di-sugar ~~residues~~ groups linked through a C atom which would carry an OH ~~residue~~ group in the sugar, wherein the sugars are independently selected from the group consisting of glucuronic acid and its stereo isomers at all optical atoms, aldopentoses, aldohexoses, including their desoxy compounds (as e.g. glucose, desoxyglucose, ribose, desoxyribose), with the mono-sugar ~~residues~~ groups such as aldopentoses, aldohexoses, including their desoxy compounds with R51, R52 which are capable of independently adopting the meaning of R21, R22,

R4, R6, R7 independently mean H, C₁-C₆ alkyl, CO-R41,


R41 independently from R21, has the same meanings as R21,

X means O, S, NH, N-R8, wherein R8 independently from R5 may adopt the same meaning as R5, or R5 and R8, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, O, and S, or X-R5 may together be H,


Y means O, S, NR9, wherein R9 may be H or C₁-C₆ alkyl,

as well their stereoisomers, tautomers, and their physiologically tolerable salts or inclusion ~~compounds~~ complexes, wherein the ~~residues~~ variable groups for Formula Ia may not concomitantly adopt the following meaning, except in case of cyclodextrin inclusion ~~compounds~~ complexes: R1: H, C₁-C₆ alkyl, R2: C₁-C₆ alkyl, C₂-C₆ alkenyl, R3: H, R4 and R6 identical, and independently H, C₁-C₆ alkyl, CO-R41, with R41 being C₁-C₆ alkyl, aryl, and R7 being H, C₁-C₆ alkyl, Y: O, and for Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X-R5 being methoxy, Y: O.

2. (Previously presented) The compounds according to claim 1, wherein Formula Ia or Ib adopts the stereochemistry of Formula IIa or IIb



II a




IIb

3. (Currently amended) The compounds of Formula Ia, Ib, IIa, IIb according to claim 2, wherein R2 has a water solubility that is at least two times higher compared to R2 being $\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{CH}_3$, with all other ~~residues~~ groups being maintained.

4. (Previously presented) The compounds according to claim 1, wherein R3 means F, Cl, Br, I, OH, OR31, NO₂, NH₂, NHR31, NR31R32, NHCHO, NHCOR31, NHCOCF₃, CH₃-_mhal_m (with hal = Cl, F, and m = 1, 2, 3), or OCOR31.

5. (Currently amended) The compounds according to claim 1, wherein R3 means (CH₂)_rCHO, (CH₂)_rCH=NOH, -(CH₂)_rCH=NOR21, (CH₂)_rCH=NOCOR21,

$(\text{CH}_2)_r\text{CH}=\text{NOCH}_2\text{CONR}_{21}\text{R}_{22}$, $(\text{CH}_2)_r\text{CH}=\text{NOCH}(\text{CH}_3)\text{CONR}_{21}\text{R}_{22}$,
 $(\text{CH}_2)_r\text{CH}=\text{NOC}(\text{CH}_3)_2\text{CONR}_{21}\text{R}_{22}$, $(\text{CH}_2)_r\text{CH}=\text{N-NHCO-R}_{23}$, $(\text{CH}_2)_r\text{CH}=\text{N-NHC}(\text{O})\text{NH-R}_{23}$,
 $(\text{CH}_2)_r\text{CH}=\text{N-NHC}(\text{S})\text{NH-R}_{23}$, $(\text{CH}_2)_r\text{CH}=\text{N-NHC}(\text{NH})\text{NH-R}_{23}$, $(\text{CH}_2)_r\text{CH}=\text{N-NHC}(\text{NH})\text{-R}_{23}$,
 $(\text{CH}_2)_r\text{CH}=\text{N-NHCO-CH}_2\text{NHCOR}_{21}$, $(\text{CH}_2)_r\text{CH}=\text{N-O-CH}_2\text{NHCOR}_{21}$,
 $(\text{CH}_2)_r\text{CH}=\text{N-NHCS-R}_{23}$, $(\text{CH}_2)_r\text{CH}=\text{CR}_{24}\text{R}_{25}$ (trans or cis), $(\text{CH}_2)_r\text{CH}=\text{NR}_{21}$, $(\text{CH}_2)_r\text{CH}=\text{N-NR}_{21}\text{R}_{22}$,




and the $(\text{CH}_2)_r$ -chain elongated residue group $(\text{CH}_2)_r\text{CH}=\text{N-N-(C}_3\text{NX'R}_{211}\text{R}_{212}\text{R}_{213}\text{R}_{214})$
 (with $\text{X}' = \text{NR}_{215}$, O, S, and R_{211} , R_{212} , R_{213} , R_{214} , R_{215} being independently H or $\text{C}_1\text{-C}_6$ alkyl), $(\text{CH}_2)_r\text{CH}=\text{N-NHSO}_2$ aryl, $(\text{CH}_2)_r\text{CH}=\text{N-NHSO}_2$ heteroaryl, with $r = 0, 1, 2, 3, 4, 5$.

6. (Previously presented) The compounds according to claim 1, wherein X means N or S, or X-R5 is OH.

7. (Previously presented) The compounds according to claim 1, wherein

R1 means H, $\text{C}_1\text{-C}_5$ alkyl, cycloalkyl,

R2 means $\text{C}_1\text{-C}_5$ alkyl, $\text{C}_1\text{-C}_4$ alkylaryl, $\text{C}_2\text{-C}_5$ alkenyl, heteroaryl, $\text{C}_1\text{-C}_4$ alkylheteroaryl,
 CHF_2 , CF_3 , polyol side chain, CH_2Y ($\text{Y} = \text{F}, \text{Cl}, \text{Br}, \text{I}$), CH_2NH_2 , $\text{CH}_2\text{NR}_{21}\text{R}_{22}$, $\text{CH}_2\text{NHCOR}_{23}$,
 $\text{CH}_2\text{NHCSR}_{23}$, CH_2SH , $\text{CH}_2\text{S}(\text{O})_n\text{R}_{21}$, with $n = 0, 1, 2$, $\text{CH}_2\text{SCOR}_{21}$, CH_2OH , $\text{CH}_2\text{OR}_{21}$,
 $\text{CH}_2\text{OSO}_2\text{-R}_{21}$, CHO , $\text{CH}(\text{OR}_{21})_2$, $\text{CH}(\text{SR}_{21})_2$, CN , $\text{CH}=\text{NOH}$, $\text{CH}=\text{NOR}_{21}$, $\text{CH}=\text{NOCOR}_{21}$,
 $\text{CH}=\text{N-NHCO-R}_{32}$, $\text{CH}=\text{CR}_{24}$, R_{25} (trans or cis), COOH , COOR_{21} , $\text{CONR}_{21}\text{R}_{22}$,
 $-\text{CH}=\text{NR}_{21}$, $-\text{CH}=\text{N-NR}_{21}\text{R}_{22}$,



(with $X' = \text{NR}_{215}, \text{O}, \text{S}$, and $\text{R}_{211}, \text{R}_{212}, \text{R}_{213}, \text{R}_{214}, \text{R}_{215}$ being independently H or $\text{C}_1\text{-C}_6$ alkyl), $-\text{CH}=\text{N}-\text{NHSO}_2$ aryl, $-\text{CH}=\text{N}-\text{NHSO}_2$ heteroaryl, or $\text{CH}=\text{N}-\text{NHCO}-\text{R}_{23}$,

$\text{R}_{21}, \text{R}_{22}$ independently mean $\text{C}_1\text{-C}_6$ alkyl, cycloalkyl, aryl, $\text{C}_1\text{-C}_4$ alkylaryl, heteroaryl, or $\text{C}_1\text{-C}_4$ alkylheteroaryl,

R_{23} independently of R_{21} , has the same meanings as R_{21} , or CH_2 -pyridinium salts, or CH_2 -tri- $\text{C}_1\text{-C}_6$ alkylammonium salts,

R_{24} independently of R_{21} , has the same meanings as R_{21} , or $\text{H}, \text{CN}, \text{COCH}_3, \text{COOH}, \text{COOR}_{21}, \text{CONR}_{21}\text{R}_{22}, \text{NH}_2$, or NHCOR_{21} ,

R_{25} independently of R_{21} , has the same meanings as R_{21} , or $\text{H}, \text{CN}, \text{COCH}_3, \text{COOH}, \text{COOR}_{21}, \text{CONR}_{21}\text{R}_{22}, \text{NH}_2$, or NHCOR_{21} ,

$\text{R}_{24}, \text{R}_{25}$ together mean $\text{C}_4\text{-C}_8$ cycloalkyl,

R_3 means $\text{F}, \text{Cl}, \text{Br}, \text{I}, \text{NO}_2, \text{NH}_2$, or NHCOR_{31} ,

R_{31} independently means $\text{C}_1\text{-C}_6$ alkyl,

R_5 means $\text{H}, \text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_8$ cycloalkyl, $\text{C}_3\text{-C}_8$ cycloalkenyl, $\text{C}_1\text{-C}_6$ alkenyl, $\text{C}_1\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_4$ alkylcycloalkyl, heterocycloalkyl, $\text{C}_1\text{-C}_4$ alkylheterocycloalkyl, aryl, $\text{C}_1\text{-C}_4$ alkylaryl, heteroaryl, $\text{C}_1\text{-C}_4$ alkylheteroaryl, $\text{C}_m\text{H}_{2m+o}\text{Y}_p$ (with $m = 1$ to 6 , for $o = 1$, $p = 1$ to

$2m+o$; for $m = 2$ to 6 , $o = -1$, $p = 1$ to $2m+o$; for $m = 4$ to 6 , $o = -2$, $p = 1$ to $2m+o$; $Y =$ independently selected from the group consisting of halogen, OH, OR21, NH₂, NHR21, NR21R22, SH, SR21), hydroxyalkyl with one or more OH groups,

R4, R6, R7 independently mean H, C₁-C₅ alkyl, or CO-R41,

R41 independently from R21, has the same meanings as R21,

X means O, S, NH, or N-R8,

Y means O, or S.

8. (Currently amended) The compounds according to claim 1 in the form of inclusion ~~compounds~~ complexes with cyclodextrin.

9. (Previously presented) Drugs containing compounds according to claim 1, a carrier and adjuvants.

10. (Original) Drugs according to claim 9 in combination with further agents for tumor treatment.

Claims 11-14 (Canceled)

15. (New) A method of treating a tumor in a patient comprising administering an effective amount of a compound of claim 1 to said patient.

16. (New) A method of treating parasites comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 1.